TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women who are at least 18 years of age, and who have a diagnosis of advanced illness with anticipated life expectancy \>= 1 month;~* Is receiving a regular dose of opioids for the control of pain;~* Has a diagnosis of opioid induced constipation;~* Is on a stable laxative regimen.~Exclusion Criteria:~* Has a known or suspected mechanical gastrointestinal obstruction, or any potential non-opioid cause of bowel dysfunction contributed to constipation;~* Has evidence of current fecal impaction;~* Has evidence of active diverticulitis, or peritonitis, or a history of bowel surgery within 30 days before test article administration;~* Has a body weight less than 27 kg~* Has any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study, or could preclude the evaluation of the subject's response.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methylnaltrexone double-blind (Type: EXPERIMENTAL): Methylnaltrexone once every other day.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once every other day.
- Methylnaltrexone open-label (Type: OTHER): Subjects who completed the double-blind period had the option to receive methylnaltrexone once every other day during a 12-week, open-label extension period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals 18-75 years old~* Fasting in Ramadan~* No daily PPI use~* Individuals willing to sign consent form~* Patients owning a smartphone and able to use a smartphone application~Exclusion Criteria:~* Known erosive GERD on PPI~* Pregnant females~* Prior gastric surgery~* Long standing diabetes mellitus (≥10 years of disease)~* Frequent NSAID use (\>3x/week)~* Morbid obesity (BMI\>35)~* History of recent (\<6 months) upper GI bleeding~* Patients who do not own a smartphone or who cannot use a smartphone application~* Known allergy to PPIs~* Known history of poor compliance or adherence and active psychological problems which might impact adherence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 34 patients will be assigned to take Dexlansoprazole 60mg over the 2nd, 3rd, and 4th weeks of the month of Ramadan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin Dose and Atherosclerosis in Patients With Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 40 to 80 years, inclusive.~2. Patients with stable coronary disease, with and without diabetes mellitus, defined by:~   1. angiographic evidence of 70% or greater stenosis, or~  2. previous percutaneous coronary intervention (PCI), or~  3. coronary artery bypass graft (CABG), or~  4. history of a MI, or~  5. positive exercise test~Exclusion Criteria:~1. Patients taking greater than 81mg aspirin daily.~2. Patients taking any of the following medications for less than 3 months, or who plan to take them for the first time during the next 3 months: ACE-inhibitors, angiotensin receptor blockers, calcium channel blockers, or statins.~3. Patients within 6 months of a coronary intervention, including PCI or CABG.~4. Patients with a planned coronary intervention.~5. Patients taking anti-platelet drugs such as clopidogrel or non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulant drugs such as warfarin.~6. Patients who are currently cigarette smokers.~7. Women patients who are pregnant, planning to become pregnant, nursing a child, or taking hormone replacement therapy.~8. Patients with any coagulation, bleeding or blood disorders.~9. Patients who are sensitive or allergic to aspirin.~10. Patients with documented history of any gastrointestinal disorders, including bleeding ulcers.~11. Patients with any evidence of cancer or kidney, liver, lung, blood, or brain disorders.~12. Patients with asthma, rhinitis, or nasal polyps.~13. Patients with any abnormal laboratory value or physical finding that, in the view of the responsible clinician, may interfere with interpretation of the trial results, be indicative of an underlying disease state, or compromise the safety.~14. Patients with Class IV heart failure.~15. Patients with severe aortic insufficiency, or aortic regurgitation.~16. Patients with hearing loss or tinnitus.~17. Patients with tremors which cause them not to be able to remain motionless for approximately 30 seconds.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 81 mg Aspirin
- 2 (Type: ACTIVE_COMPARATOR): 162 mg Aspirin
- 3 (Type: ACTIVE_COMPARATOR): 325 mg Aspirin
- 4 (Type: ACTIVE_COMPARATOR): 650 mg Aspirin
- 5 (Type: ACTIVE_COMPARATOR): 1300 mg Aspirin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria :~* Patients with type 2 diabetes mellitus diagnosed at least 1 year before the screening visit~* Patient treated for at least 3 months prior to screening visit with one of following OADs at a stable dose of at least usual maintenance dose as described in the label~  * a biguanide (metformin hydrochloride);~ * a thiazolidinedione (TZD) (pioglitazone hydrochloride);~ * an alpha-glucosidase inhibitor (alpha-GI) (acarbose, voglibose or miglitol);~ * or a glinide (nateglinide, repaglinide or mitiglinide);~* Signed written informed consent~Exclusion criteria:~* At screening HbA1c \<7% or \>9.5%;~* At screening: fasting plasma glucose \>250 mg/dL (\>13.9 mmol/L);~* Use of any glucose-lowering agent(s) other than the authorized patient's background treatment defined in I02 (as given in inclusion critieria) within 3 months prior to screening;~* Type 1 diabetes mellitus;~* Women of childbearing potential with no effective contraceptive method;~* Pregnancy or lactation;~* Laboratory findings at the time of screening:~  * Amylase and/or lipase \>3 times the upper limit of the normal laboratory range (ULN);~ * ALT \>3 ULN;~* Any contra-indication to the patient's background oral anti-diabetic treatment;~* History of acute or chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease;~* Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes);~* Any previous treatment with lixisenatide (eg, participation in a previous study with lixisenatide) or any other GLP1 receptor agonist.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lixisenatide + Biguanide (Type: EXPERIMENTAL): 52-week treatment with Lixisenatide in combination with biguanide (usual maintenance dose in the label)
- Lixisenatide + TZD (Type: EXPERIMENTAL): 52-week treatment with lixisenatide in combination with TZD (usual maintenance dose in the label)
- Lixisenatide + alpha-GI (Type: EXPERIMENTAL): 52-week treatment with Lixisenatide in combination with alpha-GI (usual maintenance dose in the label)
- Lixisenatide + Glinide (Type: EXPERIMENTAL): 52-week treatment with Lixisenatide in combination with glinide (usual maintenance dose in the label)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Colchicine for the Stability of Coronary Plaque in Acute Coronary Syndrome (COLOCT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants who understand and sign the informed consent form voluntarily.~2. Age ≥ 18 years old and ≤ 80 years old, regardless of sex.~3. hospitalized patients diagnosed with acute coronary syndrome within 1 month.~4. at least one non-culprit lesion with diameter stenosis percentage of 30% to 70% by visual estimation on coronary angiography (CAG) after completing any planned percutaneous revascularization.~5. the lesion shown by OCT was lipid-rich plaque (Lipid pool arc \> 90 °).~Exclusion Criteria:~1. Allergic to colchicine.~2. Colchicine was taken within 10 days before randomization.~3. Abnormal liver function (ALT \> 3 times the upper limit of normal value).~4. Abnormal renal function (creatinine clearance rate \< 45 ml/min).~5. Thrombocytopenia (PLT \< 100G/L).~6. Uncontrolled infectious diseases during the screening period.~7. Known immune diseases or immune-related diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumor and so on.~8. Pre-existing or plan for the administration of systemic anti-inflammatory treatments such as non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapeutic drugs.~9. History of surgery or interventional therapy within 6 months prior to the screening period.~10. A history of coronary artery bypass grafting or a plan for coronary artery bypass grafting within 1 year.~11. Left main coronary disease (≥50% reduction in lumen diameter by angiographic visual estimation).~12. Significant coronary calcification or tortuosity deemed to preclude OCT evaluation.~13. Diagnosed with mental disorders such as anxiety or depression.~14. Pregnant women, lactating women or women of childbearing age who do not use effective contraceptive methods.~15. Participated in other clinical trials within 3 months before the screening period.~16. Do not receive standardized treatment after being diagnosed with coronary heart disease.~17. The life expectancy of the subjects is less than 1 year.~18. The researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): colchicine (0.5mg), one pill a day, oral intake
- Control Group (Type: PLACEBO_COMPARATOR): placebo, one pill a day, oral intake

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults, 18 years and older~* Histologically confirmed and measurable giant cell tumor (GCT)~* Recurrent GCT confirmed by radiology or unresectable GCT~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~Exclusion Criteria:~* Pateints for whom surgery to the affected limb/area is planned within 27 days after receiving 1st dose of denosumab~* Radiation to affected region within 28 days before enrollment to study~* Known diagnosis of osteosarcoma or brown tumor of bone~* Known history of second malignancy within the past 5 years, except for basal cell carcinoma or cervical carcinoma in situ~* Concurrent treatment with bisphosphonates, calcitonin, or interferon.~Other criteria also apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: EXPERIMENTAL): Participants received denosumab 120 mg once every 4 weeks (Q4W), with an additional 120 mg doses on Days 8 and 15 of the first month of treatment. All participants were instructed to take daily supplements of at least 500 mg of calcium and 400 IU of vitamin D. Participants were to continue to receive denosumab until one of the following occurred: complete tumor resection, disease progression without clinical benefit, or decision by the participant to discontinue for any reason.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Meet criteria for primary Fibromyalgia Syndrome as defined by the American College of Rheumatology~Exclusion Criteria:~* Have any current primary Axis I diagnosis other than major depressive disorder~* Have any current or previous diagnosis of psychosis, bipolar disorder, or schizoaffective disorder~* Have any primary diagnosis of anxiety disorder within the past year (including panic disorder, agoraphobia, OCD, PTSD, GAD and social phobia)~* Have regional pain syndrome, multiple surgeries or failed back syndrome~* Have a confirmed current or previous diagnosis of rheumatoid arthritis, inflammatory arthritis, or infective arthritis, or an autoimmune disease (e.g. lupus)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* It was recommended that the patient's treatment was in accordance with the local marketing authorization (MA) for Neupro®~* The patient must have a diagnosis of moderate to severe idiopathic RLS~* The patient is considered reliable and capable of adhering to the visit schedule or medication administration according to the judgment of the investigator~* The decision to prescribe the drug has been made by the physician independently of his/her decision to include the patient in the study~* Subject is informed and given ample time and opportunity to think about his/her participation in the study and has given written informed data consent~Exclusion Criteria:~* Hypersensitivity to the active substance or to any of the excipients~* Magnetic resonance imaging or cardioversion (see SmPC)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neupro® (Type: None): Routine treatment in accordance with the local marketing authorization for Neupro® in RLS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus.~* Cardiovascular disease~* Uninterrupted anti-diabetic treatment for at least 8 weeks before enrolment~Exclusion Criteria:~* Patients with type 1 diabetes or diabetes insipidus~* Patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes~* Any clinically significant illness, which would compromise the patient's safety and their participation in the study

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): dapagliflozin 10 mg tablet
- 2 (Type: PLACEBO_COMPARATOR): matching placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Lifestyle Modification on Vestibular Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (18 years and older)~* Must meet International Classification of Headache Disorders criteria for vestibular migraine~* Must be able to read and comprehend the English language as instructions are only provided in that language~Exclusion Criteria:~* Younger than 18 years~* Do not meet IHCD criteria for vestibular migraine~* Unable to understand English language instructions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): All participants will be provided written and verbal instructions regarding the lifestyle modification intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Social and Financial Incentives to Increase Physical Activity Among Overweight and Obese Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans~* Body mass index of 25 or greater~* Access to smartphone or tablet to sync wearable device data~* Interest in participating in a 20-week physical activity program~Exclusion Criteria:~* Already participating in a physical activity research study~* Unable to provide informed consent~* Unsafe or infeasible to participate~* No access to smartphone or table to sync wearable device data

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): This arm serves as control and uses a wearable device to track daily step counts
- Social Incentive Gamification (Type: EXPERIMENTAL): This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, and selects a support sponsor
- Social Incentive Gamification and Financial Incentive (Type: EXPERIMENTAL): This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, selects a support sponsor, and receives a financial incentive

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is ≥ 18 years of age~* Subject has a diagnosis of Idiopathic Thrombocytopenia Purpura (ITP) according to the American Society of Hematology (ASH) guidelines~* If subject is \> 60 years of age, subject has a written bone marrow biopsy report confirming the diagnosis of ITP~* Subject has received at least 1 prior therapy for ITP~* Subject has a platelet count \< 50,000 or their platelet count falls to \< 50,000 during or after a clinically-indicated taper or discontinuation of current ITP therapy~* Before any study-specific procedure, the appropriate written informed consent must be obtained~Exclusion Criteria:~* Subject has had a splenectomy for any reason~* Subject has an active malignancy~* Subject has a history of cancer, other than basal cell carcinoma or cervical carcinoma in situ, with treatment or active disease within 5 years~* Subject has a known history of bone marrow stem cell disorder~* Subject has participated in any study evaluating polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO), AMG 531, or a thrombopoietic protein~* Subject is receiving other investigational agents or procedures~* Subject is currently enrolled in, or has completed within the last 30 days, another investigational device or drug study~* Subject is pregnant or breast feeding~* Subject is not using adequate contraceptive precautions~* Subject has known sensitivity to any recombinant E. coli-derived product~* Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and does not have a legally acceptable representative~* Subject has any kind of disorder that compromises the ability of the subject to comply with study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Romiplostim (Type: EXPERIMENTAL): Romiplostim administered by subcutaneous injection once weekly at a starting dose of 3 μg/kg, adjusted to a maximum dose of 10 μg/kg to maintain a platelet count between 50 and 200 x 10\^9/L for up to 52 weeks.
- Standard of Care (Type: OTHER): Medical standard of care treatments were selected and prescribed by the investigator according to standard institutional practices or therapeutic guidelines and administered for up to 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete